--Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies ...

Like Kymera, I am not prepared to give up on the protein deg story yet, and although a poor set of data, or the exit of Sanofi from the KT-474 program could derail the company's share price ...

Kymera partner Sanofi has elected to advance the biotech’s program to mid-stage testing in two inflammatory skin disorders. By Frank Vinluan on December 14, 2022 2:22 pm ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

The collaboration includes up to $85 million in upfront payments and up to $750 million in milestone payments. The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains ...

Kymera's partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 program. Find out the reasons to rate KYMR stock a Buy.

Kymera could receive as much as $975 million in milestone payments as part of its deal with Sanofi, some of which could pay out next year if the two begin clinical testing of KT-485 then.

Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474</p ...

Sanofi has informed Kymera that it will advance KT-485, Kymera's drug candidate targeting IRAK4 for immuno-inflammatory diseases, into clinical studies and not proceed with KT-474.

CAMBRIDGE, Mass., July 9, 2020 /PRNewswire/ -- Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop ...